XNASIMCR
Market cap1.51bUSD
Dec 26, Last price
30.22USD
1D
5.44%
1Q
-3.76%
IPO
-46.36%
Name
Immunocore Holdings PLC
Chart & Performance
P/E
—
P/S
4.84
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
12.35%
Rev. gr., 5y
60.18%
Revenues
249m
+73.53%
Net income
-55m
L+34.11%
CFO
3m
P
Earnings
Feb 26, 2025
Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 249,428 73.53% | 143,737 441.99% | 26,520 -11.93% | |||
Cost of revenue | 164,582 | 89,624 | 234,851 | |||
Unusual Expense (Income) | ||||||
NOPBT | 84,846 | 54,113 | (208,331) | |||
NOPBT Margin | 34.02% | 37.65% | ||||
Operating Taxes | (5,603) | (2,921) | (9,405) | |||
Tax Rate | ||||||
NOPAT | 90,449 | 57,034 | (198,926) | |||
Net income | (55,287) 34.11% | (41,224) -68.66% | (131,523) 77.51% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 116,812 | 226,528 | ||||
BB yield | -4.48% | -15.08% | ||||
| Debt | ||||||
Debt current | 1,388 | 1,555 | 1,255 | |||
Long-term debt | 118,665 | 97,551 | 89,191 | |||
Deferred revenue | 5,515 | 4,331 | 6,408 | |||
Other long-term liabilities | 978 | 1,593 | 57 | |||
Net debt | (322,573) | (233,570) | (152,375) | |||
| Cash flow | ||||||
Cash from operating activities | 2,940 | (31,269) | (129,749) | |||
CAPEX | (4,256) | (2,197) | (1,008) | |||
Cash from investing activities | (5,425) | 233 | (495) | |||
Cash from financing activities | 34,346 | 138,226 | 276,252 | |||
FCF | 79,359 | 56,926 | (193,616) | |||
| Balance | ||||||
Cash | 442,626 | 332,539 | 237,886 | |||
Long term investments | 137 | 4,935 | ||||
Excess cash | 430,155 | 325,489 | 241,495 | |||
Stockholders' equity | (780,801) | 73,594 | (95,048) | |||
Invested Capital | 1,244,284 | 279,462 | 336,364 | |||
ROIC | 11.87% | 18.52% | ||||
ROCE | 18.47% | 15.33% | ||||
| EV | ||||||
Common stock shares outstanding | 48,889 | 45,715 | 43,863 | |||
Price | 68.32 19.71% | 57.07 66.68% | 34.24 | |||
Market cap | 3,340,095 28.02% | 2,608,951 73.71% | 1,501,864 | |||
EV | 3,017,522 | 2,375,381 | 1,349,489 | |||
EBITDA | 88,936 | 60,244 | (201,319) | |||
EV/EBITDA | 33.93 | 39.43 | ||||
Interest | 5,154 | 7,692 | 5,813 | |||
Interest/NOPBT | 6.07% | 14.21% | ||||